Remote 6-Minute-Walk Testing in Patients with Pulmonary Hypertension: Further Validation Needed?

To the Editor:

The 6-minute-walk test (6MWT) provides insight on functional status, disease severity, and therapeutic efficacy in people with chronic lung disease. The need for digital-technology enabled healthcare provisions that mitigate in-clinic patient visits accelerated during the coronavirus disease (COVID-19) pandemic. Accordingly, the report of LaPatra and colleagues (1) in the April 1 issue of the Journal on the feasibility, safety, and accuracy of performing “remote” 6MWTs in nonclinical settings for pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) is timely and promising. Using and incorporating locations chosen by study participants, audiovisual guidance from study personnel, and companion “support” for each participant, the authors found “no systematic difference” in average 6MWT distance (6MWD) between in-clinic versus remote settings, with excellent concordance between the in-clinic and remote walks. Other than in one patient (lightheadedness, tinnitus), no adverse events were reported during the remote walks. The authors did, however, find that 6MWD was shorter (~20 m) in masked versus unmasked participants during remote walks. While acknowledging that their findings require replication, the authors conclude that remote 6MWTs may be feasible and valid in stable patients with PH.

We applaud the authors for their work; however, two aspects of their findings require replication, the authors conclude that remote 6MWD with versus without a facemask, with better clustering of data points around the perfect concordance line (see Figure 2 in original report) (1). Two questions arise: 1) do patients with lower exercise capacity (presumably sicker patients) perform better during in-clinic versus remote walk tests; and 2) despite no difference in group mean 6MWD in-clinic versus remote settings, could substantial intra-individual heterogeneity exist in the concordance between in-clinic and remote 6MWTs? Speculatively, it is possible that sicker patients with more impairment “perform better” in clinical settings secondary to direct supervision from healthcare professionals, making remote-based 6MWTs less appropriate in such individuals. Also, given that 6MWD differed by ~50 m in-clinic compared with remote settings in ~40% of patients, we suggest that the applicability of remote-based 6MWT as an accurate and valid marker of functional status, disease severity, and therapy efficacy requires further validation.

Author disclosures are available with the text of this letter at www.atsjournals.org.

Scott A. Helgeson, M.D.
Charles D. Burger, M.D.
John E. Moss, M.D.
Tonya K. Zeiger, R.R.T.
Bryan J. Taylor, Ph.D.∗
Mayo Clinic
Jacksonville, Florida

ORCID IDs: 0000-0001-7590-2293 (S.A.H.); 0000-0001-5229-941X (B.J.T.).

∗Corresponding author (e-mail: taylor.bryan@mayo.edu).

References

1. LaPatra T, Baird GL, Goodman R, Pinder D, Gaffney M, Klinger JR, et al. Remote 6-minute-walk testing in patients with pulmonary hypertension: a pilot study. Am J Respir Crit Care Med 2022;205:851–854.
From the Authors:

We read with interest the letter by Helgeson and colleagues and appreciate the opportunity to continue this important and timely discussion on the value of remote 6-minute-walk testing (6MWT) in pulmonary hypertension (PH). We agree that the risk versus benefit of in-clinic unmasked walks is unfavorable given concerns about communicable respiratory viruses (including severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) in our vulnerable patient population. We acknowledge that our study (1) requires additional validation in more settings and in more patients and applaud the recent work by Helgeson and colleagues (2) to this end. For the sake of discussion, we raise the following points.

While it is certainly possible that masking does not impact 6-minute-walk distance (6MWD), we note that in studies where conditions like masking are compared retrospectively, it is not possible to control for an order effect. As the order (masked versus unmasked) is not randomly counterbalanced, correlation cannot be distinguished from causation. In our prospective study, the order of 6MWTs was performed at random and we completed all walks over a six-week period, which is approximately half the time of the in-clinic walks reported by Helgeson and colleagues. It is possible that a temporal effect confounded the results of both studies. As masking cannot be blinded, perceived exertion during a masked 6MWT may be subject to reporting and recall bias. Swiatek and colleagues did randomize facemask order in their design with healthy participants whom they did not randomize facemask order in our study, the systematic bias we observed whereby masked participants achieved shorter 6MWD than when unmasked could be caused by cardiopulmonary limitations due to PH, psychology, or both. The act of wearing a facemask may cause patients to perceive a restriction of air, which may negatively influence exercise capacity; likewise, wearing a facemask may lead to self-regulation and shorter 6MWD.

Surprisingly, in our study Borg Scales for breathlessness and fatigue were concordant in masked versus unmasked walks and not significantly different (Figure 1). As pointed out by Helgeson and colleagues, an observer effect is also possible—patients may perform better (or worse) in front of clinical staff or trusted companions. Studies manipulating observers and real versus sham facemasks (facemasks with all layers removed but the paper top) could be designed to address these limitations. Of course, to demonstrate evidence of “no difference” with any intervention, a study must be (a priori) designed and powered to test for either noninferiority or equivalence. Alternatively, concordance can be evaluated, as we have done here.

Second, the distinction between absolute versus relative differences in walk distance should be considered. For example, take a subject who walked 375 m in-clinic (at the lower end of the distribution in our study) but achieved 400 m remotely—a “moderate” absolute difference of 25 m and a relative increase of 7%—and compare this to a second subject who walked 600 m in-clinic (the upper end of the distribution) but 650 m remotely—a “large” discrepancy of 50 m but only an 8% relative increase. The discrepancy of the latter participant is twice as large as that of the former and surpasses the minimally important difference, though the relative differences are nearly the same (7% vs. 8%). It is for this reason that comparing absolute distances between participants on different ends of a spectrum should be done with caution. To further address this issue, we natural-log transformed distance from our centers, while remote was not. Conversely, there was less variation in conditions and likely familiar to all participants as established patients at our centers. Being remote was not. Conversely, there was less noise in the mask analysis. As in-clinic is a controlled setting and likely familiar to all participants as established patients at our centers, while remote was not. Conversely, there was less noise in the mask analysis. As the fourth walk in our study was optional (and the walk used to compare masking), we may have selected for PH participants who were willing to do the extra walk, healthier, and more prone to a ceiling effect. It is our hope that larger, prospective studies can address these gaps in studies to-date on this topic as we integrate mobile health into the care of patients with PH.